Viagra and Levothyroxine Interaction: What You Need to Know

Why This Combination Comes Up So Often

Hypothyroidism and erectile dysfunction (ED) frequently coexist in men over 40. A 2018 cross-sectional analysis published in the International Journal of Impotence Research found that men with subclinical hypothyroidism had a 2.3-fold higher odds ratio for ED compared to euthyroid controls (Corona et al., 2018). That overlap means prescribers routinely encounter patients taking levothyroxine who request sildenafil, or vice versa. The interaction question is practical, not theoretical.

The Clinical Scenario

A typical patient is a 52-year-old man on levothyroxine 100 mcg daily for primary hypothyroidism, now presenting with ED. His TSH is at goal (1.2 mIU/L), and he wants to try sildenafil 50 mg as needed. His physician checks for drug interactions. Nothing flags.

Why Patients Still Worry

Online drug interaction checkers vary in how they classify this pair. Some list a "minor" interaction. Others show no result at all. That inconsistency drives patient anxiety, even when the pharmacology is straightforward.

Pharmacokinetic Analysis: Metabolism and Absorption

Sildenafil and levothyroxine travel through the body by entirely separate metabolic routes. Understanding those routes explains why a meaningful pharmacokinetic interaction is unlikely.

Sildenafil's CYP3A4 Pathway

Sildenafil undergoes extensive first-pass hepatic metabolism, primarily via cytochrome P450 3A4 (CYP3A4), with a minor contribution from CYP2C9 (FDA, Viagra label). Its major active metabolite, N-desmethyl sildenafil, retains roughly 50% of the parent compound's potency for phosphodiesterase type 5 (PDE5). Drugs that inhibit CYP3A4 (ketoconazole, ritonavir, erythromycin) raise sildenafil plasma levels significantly. Drugs that induce CYP3A4 (rifampin, carbamazepine) lower them.

Levothyroxine does neither. It is not a CYP3A4 inhibitor, inducer, or substrate.

Levothyroxine's Non-CYP Metabolism

Levothyroxine (T4) is converted to triiodothyronine (T3) by selenium-dependent deiodinase enzymes in the liver, kidneys, and peripheral tissues (FDA, Synthroid label). It is also conjugated via glucuronidation and sulfation before biliary and renal excretion. None of these steps involve CYP3A4 or CYP2C9. The two drugs simply do not compete for the same enzymatic machinery.

Absorption Considerations

Levothyroxine absorption is notoriously sensitive to gastric pH, calcium, iron, and food. Anything that raises gastric pH (proton pump inhibitors, antacids) can reduce levothyroxine bioavailability by up to 30% (Irving et al., 2015). Sildenafil does not alter gastric acid secretion or pH. It also does not chelate levothyroxine the way calcium or ferrous sulfate would. No P-glycoprotein (P-gp) competition has been documented between the two drugs.

The standard guidance still applies: take levothyroxine on an empty stomach, 30 to 60 minutes before any other medication or food. If a patient follows that rule, sildenafil (taken hours later, as needed before sexual activity) poses no absorption conflict.

Pharmacodynamic Considerations: Thyroid Status and Cardiovascular Risk

The more clinically relevant concern is not a drug-drug interaction. It is the cardiovascular context that thyroid disease creates.

Hypothyroidism and Hemodynamics

Untreated or undertreated hypothyroidism raises diastolic blood pressure, increases systemic vascular resistance, and accelerates atherosclerosis (Razvi et al., 2018). These hemodynamic changes can worsen both ED and cardiovascular risk. Sildenafil causes systemic vasodilation and a modest drop in blood pressure (8/5 mmHg on average). In a patient with compensated, well-treated hypothyroidism, that effect is clinically benign. In a patient with uncontrolled hypothyroidism and concurrent diastolic hypertension, the hemodynamic picture is less predictable.

Hyperthyroidism: The Opposite Risk

Overreplacement with levothyroxine (TSH <0.1 mIU/L) causes a hyperthyroid state: tachycardia, widened pulse pressure, and increased cardiac output. Adding sildenafil's vasodilatory effect on top of a hyperkinetic circulation could, theoretically, increase the risk of symptomatic hypotension or palpitations. No controlled trial has specifically studied this combination in thyrotoxic patients, but the physiological reasoning supports caution.

The Practical Rule

Confirm that TSH is at goal before prescribing sildenafil. If TSH is suppressed below range or elevated above 10 mIU/L, address thyroid status first. A euthyroid patient on stable levothyroxine can use sildenafil without additional cardiovascular precautions beyond the standard ED workup.

What the Interaction Databases Say

Major drug interaction databases classify this pair consistently at the lowest tier of concern.

Database Ratings

Lexicomp, Micromedex, and Clinical Pharmacology do not list a direct interaction between sildenafil and levothyroxine. The Drugs.com interaction checker returns "no known interaction." UpToDate's drug interaction tool also shows no result for this pair.

FDA Label Cross-Reference

The Viagra prescribing information lists CYP3A4 inhibitors, CYP3A4 inducers, alpha-blockers, nitrates, riociguat, and antihypertensives as relevant interacting drug classes (FDA, Viagra label). Thyroid hormones are absent from the list. The Synthroid prescribing information lists oral anticoagulants, cardiac glycosides, antidiabetic agents, antacids, bile acid sequestrants, calcium, and iron as interacting agents (FDA, Synthroid label). PDE5 inhibitors are not mentioned.

Why Some Checkers Flag It Anyway

A handful of consumer-grade interaction checkers label any combination of two prescription drugs as a "minor" interaction by default. This is a classification artifact, not a pharmacological finding. If a patient sees a flag online, the appropriate response is reassurance grounded in the mechanism data above.

Monitoring Recommendations for Patients on Both Drugs

Even in the absence of a direct interaction, coordinated monitoring protects patients against indirect risks.

Baseline Workup Before Starting Sildenafil

The American Urological Association (AUA) recommends a cardiovascular risk assessment before prescribing PDE5 inhibitors, including resting blood pressure, fasting lipids, and fasting glucose (Burnett et al., 2018). For patients on levothyroxine, add a recent TSH (within 6 to 12 weeks) to confirm euthyroid status.

Ongoing Thyroid Monitoring

If a patient's levothyroxine dose changes, recheck TSH in 6 to 8 weeks. Dose adjustments can shift cardiovascular parameters enough to alter the hemodynamic response to sildenafil. No sildenafil dose adjustment is required based on thyroid status alone, but if a patient reports new-onset dizziness, lightheadedness, or palpitations after a levothyroxine dose change, reassess both medications in context.

When to Recheck

Recheck TSH if the patient:

• Switches levothyroxine brands or formulations (Synthroid to generic, tablet to liquid)
• Starts a new medication that affects levothyroxine absorption (calcium, iron, a PDE5 inhibitor is not in this category)
• Reports symptoms of over- or underreplacement (fatigue, weight change, heat intolerance, cold intolerance)

Dose Adjustments: Are Any Needed?

No dose adjustments to either sildenafil or levothyroxine are required when the two are used together.

Sildenafil Dosing Remains Standard

The recommended starting dose of sildenafil for ED is 50 mg, taken approximately 1 hour before sexual activity (FDA, Viagra label). The dose can be adjusted to 25 mg or 100 mg based on efficacy and tolerability. Thyroid status does not alter sildenafil's pharmacokinetics enough to warrant a non-standard starting dose.

Levothyroxine Dosing Remains TSH-Driven

Levothyroxine dosing is titrated to TSH, typically targeting 0.5 to 2.5 mIU/L for most adults (Jonklaas et al., 2014). The addition of sildenafil does not change TSH, T4, or T3 levels. No guideline recommends adjusting levothyroxine because of concomitant PDE5 inhibitor use.

The Real Drug Interactions to Watch

Patients asking about Viagra and levothyroxine often take other medications too. The interactions that matter are elsewhere.

Sildenafil's Dangerous Interactions

Nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) are absolutely contraindicated with sildenafil. The combination can cause profound, life-threatening hypotension. Alpha-blockers (doxazosin, tamsulosin) carry a risk of additive hypotension. Potent CYP3A4 inhibitors like ritonavir increase sildenafil AUC by 1,100% (FDA, Viagra label), requiring a maximum dose of 25 mg per 48 hours.

Levothyroxine's Absorption Pitfalls

Calcium carbonate reduces levothyroxine absorption by up to 25% (Singh et al., 2000). Ferrous sulfate reduces absorption by a similar magnitude. Proton pump inhibitors impair absorption in patients who depend on acidic gastric pH for tablet dissolution. Cholestyramine and other bile acid sequestrants bind levothyroxine in the gut. These are the interactions that require spacing, reformulation, or dose adjustment.

A Common Polypharmacy Scenario

A man on levothyroxine 125 mcg, atorvastatin 40 mg, amlodipine 5 mg, and sildenafil 50 mg as needed. The levothyroxine-atorvastatin pair has no interaction. The amlodipine-sildenafil pair produces additive blood pressure lowering, which is usually mild but worth noting. The levothyroxine-sildenafil pair is pharmacologically inert. In this scenario, the amlodipine deserves more attention than the levothyroxine.

Thyroid Disease and Erectile Function: The Underlying Link

Thyroid dysfunction itself is an underrecognized cause of ED. Treating the thyroid problem sometimes resolves the sexual dysfunction without PDE5 inhibitors.

Hypothyroidism and ED Prevalence

A prospective Italian study of 48 men with hypothyroidism found that 64.3% reported ED at baseline (Carani et al., 2005). After achieving euthyroid status with levothyroxine for a median of 8.8 months, ED resolved in a significant proportion without any additional therapy.

The Mechanism

Thyroid hormones modulate nitric oxide synthase expression in penile vascular endothelium. Low T3 reduces nitric oxide bioavailability, which is the same pathway that sildenafil targets downstream via PDE5 inhibition (Ozdemirci et al., 2001). Restoring T3 to normal levels may improve the endogenous nitric oxide signal enough to restore erectile function, or at minimum improve the response to sildenafil.

Clinical Implication

If a man presents with both new-onset ED and untreated hypothyroidism, optimize levothyroxine first. Reassess ED after TSH normalizes. If ED persists at euthyroid status, then add sildenafil. This sequence avoids unnecessary polypharmacy and addresses the root cause.

Patient Counseling Points

Clinicians prescribing both medications should cover these points directly with patients.

Timing

Take levothyroxine first thing in the morning on an empty stomach with water only. Wait at least 30 to 60 minutes before eating or taking other medications. Sildenafil is taken as needed, typically in the evening, so the two doses are naturally separated by many hours.

What to Report

Tell your prescriber if you experience new palpitations, excessive fatigue, unexplained weight changes, or dizziness after starting sildenafil. These symptoms could reflect a thyroid dose that needs adjustment, not a drug interaction.

Refill Coordination

If your levothyroxine brand or formulation changes at the pharmacy (e.g., from brand-name Synthroid to a generic), request a TSH recheck in 6 to 8 weeks. Bioequivalence between levothyroxine products is not guaranteed at the individual patient level, and a shift in thyroid status could indirectly affect your cardiovascular response to sildenafil.

Patients on stable levothyroxine with a documented TSH in the 0.5 to 2.5 mIU/L range can use sildenafil 25 to 100 mg as needed without additional lab monitoring specific to the combination (Jonklaas et al., 2014).